Syngene Ltd
Overview
Syngene has a strong patent portfolio in the gene-based diagnostic technology known as in situ hybridisation. This portfolio is available for licensing. Syngene is also a major shareholder in the listed Antisense Therapeutics Limited.
Competitive advantages
Strong IP position and high quality research facilities and personnel based at the Florey Institute.
Partners
Several licensees of technology, including Roche Diagnostics and Novocastra Laboratories.
Main business focus/
Listing by sector:
- Medical Devices - In vitro diagnostic devices (IVD)
- Diagnostics
Competitive Advantages
Strong IP position and high quality research facilities and personnel based at the Florey Institute.
Technology/IP
Focus is on gene based diagnostics and therapeutics, leveraging patent portfolio.
Partnering Opportunities
Licensing opportunities for in situ hybridisation and novel methods for conjugation to oligonucleotides.
Partnering Needs
Principally licensing, at this stage, but other partnering opportunities will evolve as research projects mature.
Contact Details
| Contact person | Mr Robert Klupacs |
|---|---|
| Job Title | Managing Director |
| Address | 10 Wallace Avenue |
| City/Suburb | Toorak |
| State | Victoria |
| robert.klupacs@circadian.com.au | |
| Phone | +61 3 9826 0399 |
| Fax | +61 3 9824 0083 |
